secwatch.observer — SEC 8-K summary
======================================

Issuer:     Tectonic Therapeutic, Inc. (TECX)
CIK:        0001681087
Form:       8-K
Filed at:   2022-12-07T23:59:59+00:00
Accession:  0001140361-22-044662
Event type: other_material
Sentiment:  positive
Materiality: 0.85
Item codes: 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

AVROBIO reports positive clinical data for Gaucher gene therapy; plans Phase 2/3 trial for GD3 in H2 2023
--------------------------------------------------------------------------------

- GD3 pediatric patient (age 11) shows normalized GCase enzyme and biomarker; remains off ERT/SRT 15 months post AVR-RD-02; no new neurological signs.
- Four GD1 patients: liver volume reduced up to 24%, spleen up to 23%; lyso-Gb1 decreased 21%-70% below ERT baseline.
- AVROBIO plans global, randomized Phase 2/3 trial for GD3 in H2 2023, ~40 patients, 1:1 gene therapy vs. ERT, following FDA/MHRA feedback.
- No drug-related AEs; all AEs related to conditioning or underlying disease, mostly mild/moderate.
- plato platform late-stage ready; no major CMC changes anticipated for late-stage trials.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1681087/000114036122044662/0001140361-22-044662-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1681087/000114036122044662/ny20005640x4_8k.htm
  HTML page:      https://secwatch.observer/filing/0001140361-22-044662

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer